Emerging studies suggest Retatrutide , a dual stimulator targeting both GLP-1 and GIP , could offer a promising step forward for obesity management . Preliminary human tests have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost